Packard BioScience
This article was originally published in The Gray Sheet
Executive Summary
Maker of instruments and related consumables for the life sciences research market, including drug discovery, genomics and biochip analysis, goes public April 20 via an initial offering of 12 mil. shares at $9 each and grosses $108 mil. The proceeds are tabbed for debt repayment, R&D, and general corporate purposes (1"The Gray Sheet" April 3, p. 22). Underwriters include Merrill Lynch, Chase H&Q, Robert Baird & Co., Banc of America Securities, and Thomas Weisel Partners